All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib

Ophélie Cassuto(Centre Henri Becquerel), Patrick Auberger(Inserm)
Oncotarget
November 14, 2012
Cited by 34


Related Papers